阿仑膦酸钠用药持有率与二次髋部骨折风险:台湾11年人群队列研究
该研究基于台湾全民健康保险研究数据库,纳入2000-2010年50岁以上首次髋部骨折且骨折前未使用抗骨质疏松药物的患者,比较不同阿仑膦酸钠用药持有率(MPR)与二次髋部骨折风险的关系。匹配后共纳入38,675例患者,随访至2012年底,结果显示MPR≥50%时二次髋部骨折风险显著降低,且随MPR升高风险进一步下降。
要点
- 阿仑膦酸钠MPR 50-75%者二次髋部骨折风险低于未用药者(HR 0.66)。
- MPR升至75-100%时风险进一步降低(HR 0.61)。
- 首次髋部骨折后一年内MPR≥50%即可降低二次骨折风险。
核心结论
- 首次髋部骨折后一年内阿仑膦酸钠MPR≥50%可降低二次髋部骨折风险,且MPR越高风险越低。
研究设计与样本
- 基于台湾全民健康保险研究数据库的人群队列研究,纳入2000-2010年50岁以上首次髋部骨折且骨折前未使用抗骨质疏松药物的患者。
- 队列含新使用阿仑膦酸钠者9278例与未使用者79042例,未使用者按4:1匹配作为对照组。
- 匹配后共纳入38675例患者,其中女性20363例(52.7%),未用药者30940例(80%)。
主要发现
- 随访至2012年12月31日,共2392例发生二次髋部骨折,发病率为1449/100000人年。
- 与未用药者相比,阿仑膦酸钠MPR 50-75%者二次髋部骨折风险降低(HR 0.66)。
- MPR升至75-100%时,风险进一步降低(HR 0.61)。
关键数值与推荐
- 首次髋部骨折后一年内阿仑膦酸钠MPR≥50%可降低二次髋部骨折风险。
- MPR 50-75%对应的二次髋部骨折风险HR为0.66。
- MPR 75-100%对应的二次髋部骨折风险HR为0.61。
临床怎么用
- 对首次髋部骨折的骨质疏松患者,应建议阿仑膦酸钠治疗并维持一年内MPR≥50%以降低二次骨折风险。
- 用药过程中可通过提高MPR(向75-100%靠拢)进一步降低二次髋部骨折风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Alendronate is effective in preventing second hip fracture in osteoporotic patients. However, no consensus exists on the duration that is effective in preventing a second hip fracture. Our study demonstrated that risk can be reduced when the prescription is ≥ 6 months for the year following the index hip fracture. INTRODUCTION: Alendronate is effective in preventing second hip fracture in osteoporotic patients. However, no consensus exists on the accurate medication possession ratio (MPR) that is effective in preventing a second hip fracture. Our objective was to compare the risk of second hip fracture in patients treated with different MPR of alendronate. METHODS: In this population-based cohort study, data from National Health Insurance Research Database of Taiwan were analyzed. Patients 50 years and older who had an index hip fracture and were not receiving any osteoporotic medications before their fracture during 2000-2010 were included. The cohort consisted of 88,320 patients who were new alendronate users (n = 9278) and non-users (n = 79,042). Those without alendronate were matched 4:1 as the control group. Patients were subdivided into those with no medication, MPR < 25%, MPR 25-50%, MPR 50-75%, and MPR 75-100%. Cox proportional hazard models were used to calculate the adjusted hazard ratios for different MPRs of alendronate. RESULTS: After matching, 38,675 patients were included in this study; 20,363 (52.7%) were women, and 30,940 (80%) patients were without medication of alendronate. During follow-up on December 31, 2012, 2392 patients had a second hip fracture, for an incidence of 1449/100,000 person-years. Patients with alendronate MPR 50-75% had a lower risk of a second hip fracture compared to non-users (hazard ratio 0.66). When the MPR increased to 75-100%, the hazard ratio decreased to 0.61. CONCLUSIONS: In this population-based cohort study, risk of a second hip fracture can be reduced when the alendronate MPR is ≥ 50% for the year following the index hip fracture. As the MPR increases, the risk of a second hip fracture decreases.
引用
- Chen YJ, Kung PT, Chou WY, et al. Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan. Osteoporos Int. 2020. PMID: 32221674. doi:10.1007/s00198-020-05399-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。